# China Drug Infusion System Market

> China Drug Infusion System Market Research Report By Product Type (Elastomeric Infusion System, Disposable Infusion System), By Application (Oncology/Chemotherapy), By Mode of Administration (Intravenous), andBy End User (Hospitals) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.34%
- **2024:** $ 740.25 Million
- **2025:** $ 779.78 Million
- **2035:** $ 1,312 Million
- **Key Players:** Baxter International (US), B. Braun Melsungen AG (DE), Medtronic (US), Smiths Medical (US), Fresenius Kabi (DE), Terumo Corporation (JP), ICU Medical (US), Halyard Health (US), Zyno Medical (US)

**Report ID:** MRFR/Pharma/54782-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-drug-infusion-system-market-56548

---

## Market Summary

## **China Drug Infusion System Market Overview**

As per MRFR analysis, the China Drug Infusion System Market Size was estimated at 648.75 (USD Million) in 2023. The China Drug Infusion System Market Industry is expected to grow from 750 (USD Million) in 2024 to 1,150 (USD Million) by 2035. The China Drug Infusion System Market CAGR (growth rate) is expected to be around 3.962% during the forecast period (2025 - 2035).

### **Key China Drug Infusion System Market Trends Highlighted**

In the China Drug Infusion System Market, there is a notable shift towards the integration of smart technology. Advanced drug infusion systems, equipped with wireless connectivity and data analytics, are being adopted to improve patient safety and streamline healthcare operations. This trend aligns with the Chinese government's focus on enhancing healthcare quality and efficiency through digital health initiatives.

Additionally, the increasing prevalence of chronic diseases in the country drives the demand for precise and user-friendly infusion devices. With an aging population and rising awareness of quality healthcare, there is a strong market driver for innovations in drug delivery systems. Additionally, the implementation of government policies that promote the advancement of medical technology is creating market opportunities.

The "Healthy China 2030" initiative prioritizes the enhancement of healthcare infrastructure, which is anticipated to result in the increased implementation of efficient drug infusion systems in hospitals throughout the country. Furthermore, manufacturers have the opportunity to consider forming partnerships with healthcare providers in order to create customized solutions that are specifically designed to satisfy the unique requirements of the Chinese patient demographic, which is becoming more diverse.

In China, there has been a recent increase in the emphasis on patient-centered care. Infusion devices are being developed with the patient experience in mind, with a focus on simplicity of use and comfort, in addition to the needs of clinicians. The healthcare sector's evolution and the growing significance of patient engagement in treatment are the driving forces behind this change.

The ongoing transformation of the drug infusion landscape in China is exemplified by the encouragement of companies to innovate and introduce user-friendly technologies that improve the overall patient experience of treatment.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **China Drug Infusion System Market Drivers**

#### **Increasing Prevalence of Chronic Diseases**

The China Drug Infusion System Market Industry is significantly driven by the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes. According to the National Health Commission of the People's Republic of China, chronic diseases account for over 80% of total deaths annually in the country, with figures indicating that an estimated 1 in 5 adults is suffering from high blood pressure. As the population ages, the demand for effective drug infusion systems rises, promoting market growth.

Major healthcare institutions like the China Medical Association are actively influencing government health policies to enhance treatment avenues for chronic disease patients, therefore creating a conducive environment for the China Drug Infusion System Market's expansion.

#### **Technological Advancements in Infusion Systems**

The rapid technological advancements in drug infusion systems serve as a prominent driver for the China Drug Infusion System Market Industry. Innovations such as smart infusion pumps and electronic infusion devices enhance the accuracy and efficacy of drug delivery. A recent initiative by the Ministry of Science and Technology of the People's Republic of China emphasizes the development of advanced healthcare technologies, allocating substantial funding for Research and Development in this sector.

This shift towards advanced medical technologies has seen the infusion systems market flourish, with notable contributions from companies like Mindray Medical International providing cutting-edge solutions that streamline infusion processes.

#### **Growing Investments in Healthcare Infrastructure**

The ongoing investments to upgrade healthcare infrastructure in China significantly impact the growth of the China Drug Infusion System Market Industry. The government has been increasing its healthcare budget, with the National Health Commission reporting a targeted increase in total healthcare expenditure, reaching 7% of the GDP by 2025. China's commitment to improving its healthcare facilities and ensuring the availability of modern medical equipment is evident through the establishment of numerous hospitals and clinics, particularly in rural areas.

This expansion fosters a higher demand for drug infusion systems to keep pace with the growing patient population and enhances competitive positioning for key players in the market.

### **China Drug Infusion System Market Segment Insights**

#### **Drug Infusion System Market Product Type Insights**

The China Drug Infusion System Market comprises various product types that cater to diverse medical needs and enhance treatment efficiency. Among these, the Elastomeric Infusion System has gained traction due to its advantages in delivering medication steadily over an extended period, making it ideal for outpatient care and home therapies. This system is appreciated for its simplicity, reduced need for power sources, and flexibility in various clinical settings, contributing to its growing adoption among healthcare professionals.

The ability to administer a wide range of drugs safely and effectively further positions the Elastomeric Infusion System as a critical player in the market. On the other hand, the Disposable Infusion System is recognized for its convenience and minimizing the risk of cross-contamination. With increasing concerns about infection control and patient safety, the Disposable Infusion System plays a crucial role in hospital settings, ensuring that each patient receives a fresh and sterile infusion setup. This system not only enhances the reliability of drug delivery but also aligns with the healthcare industry's shift towards single-use equipment to improve hygiene standards.

Overall, both product types reveal significant contributions to the growth and transformation of the China Drug Infusion System Market, reflecting ongoing trends toward patient-centric care and innovative medical solutions tailored to evolving healthcare needs.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Drug Infusion System Market Application Insights**

The Application segment of the China [Drug Infusion System Market](../../../reports/drug-infusion-system-market-6207) plays a crucial role in meeting the diverse healthcare needs of patients, particularly in the field of Oncology/Chemotherapy. This segment is characterized by the increasing prevalence of cancer in China, which has led to an upward trend in the demand for effective drug infusion systems. With the government focusing on enhancing cancer care and improving therapeutic outcomes, Oncology/Chemotherapy applications are significant for facilitating targeted drug delivery, thus optimizing treatment protocols.

The growing number of hospitals and specialized cancer treatment centers across China is also bolstering the importance of this segment. Additionally, advancements in technology that enhance the precision and safety of drug infusion processes continue to drive interest and investment in this area. As patients undergo chemotherapy, the need for reliable and efficient drug infusion systems becomes paramount, indicating a pivotal market opportunity aligned with China's healthcare objectives.

The increasing incidence of cancer, coupled with advancements in medical technology, positions the Oncology/Chemotherapy application as a substantial contributor to the overall growth of the China Drug Infusion System Market, making it an essential focus area for development and research.

#### **Drug Infusion System Market Mode of Administration Insights**

The Mode of Administration segment within the China Drug Infusion System Market plays a critical role in ensuring the effective delivery of medications, especially in healthcare settings. One of the significant methods in this segment is Intravenous (IV) administration, which is widely used due to its rapid onset of action and effectiveness in delivering fluids, nutrients, and medications directly into the bloodstream. This method stands out for its ability to maintain precise control over drug dosage, making it essential for critically ill patients and those undergoing complex treatments.

The China Drug Infusion System Market is witnessing advancements in IV technology, driven by the increasing prevalence of chronic diseases, the aging population, and a growing focus on patient safety and comfort. Moreover, the shift towards home healthcare is also bolstering the demand for innovative IV infusion systems that offer convenience and flexibility. Challenges such as the risk of infections and complications from IV lines remain pertinent, prompting ongoing Research and Development efforts to enhance safety and usability. Overall, advancements in delivery methods, particularly IV administration, illustrate the evolving landscape of the China Drug Infusion System Market.

#### **Drug Infusion System Market End User Insights**

The End User segment of the China Drug Infusion System Market highlights the critical role of hospitals, which are central to the healthcare infrastructure in the country. Hospitals utilize drug infusion systems to administer medications safely and efficiently to patients, making this segment a significant contributor to market dynamics. With China's growing population and increasing prevalence of chronic diseases, the demand for advanced medical equipment, including drug infusion systems, is on the rise within hospital settings.

These institutions are adopting sophisticated technologies to enhance patient care, streamline operations, and comply with regulatory standards. Furthermore, as urban areas continue to expand and healthcare facilities modernize, hospitals are expected to increasingly invest in these systems. This trend is supported by government initiatives aimed at improving healthcare delivery and increasing investments in hospital infrastructure. Overall, the importance of hospitals within the China Drug Infusion System Market is underscored by their majority holding of the End User segment, driven by ongoing growth in healthcare spending and rising patient care demands.

### **China Drug Infusion System Market Key Players and Competitive Insights**

The China Drug Infusion System Market is experiencing significant growth due to increasing healthcare investments, an expanding patient population, and heightened demand for advanced medical technologies. This market is characterized by a diverse range of players, including established companies and emerging startups that are all vying for a share in this expanding sector. Competition in this market is driven by various factors, including technological advancements, pricing strategies, and the ability to offer customized solutions to meet the specific needs of healthcare providers.

Players in the market are also focusing on improving their production capabilities and enhancing their product portfolios to capture a larger audience, while regulatory compliance and safety standards are equally pivotal in determining market success. As hospitals and medical institutions increasingly adopt drug infusion systems for better patient care, understanding the competitive landscape is essential for identifying growth opportunities and potential challenges within this dynamic market.

Zhejiang Shunfeng has established itself as a key player in the China Drug Infusion System Market with a solid reputation for providing high-quality and reliable medical devices. The company has a robust manufacturing framework that allows it to cater to the growing demand for infusion systems across various healthcare providers in China. One of its notable strengths lies in its commitment to innovation, which is evident in its ability to rapidly advance new products that incorporate the latest technology.

Additionally, Zhejiang Shunfeng has formed various strategic partnerships with healthcare institutions and is well-regarded for offering cost-effective solutions that address diverse medical needs. This agile approach helps the company maintain a competitive edge in the market while also enhancing its overall brand presence domestically.

Becton Dickinson plays a significant role in the China Drug Infusion System Market, primarily known for its extensive range of medical technologies and devices that focus on medication delivery. The company offers a variety of products, including infusion pumps and related accessories, which are widely utilized in hospitals and clinics throughout China. Becton Dickinson's strengths lie in its continuous investment in research and development, allowing for innovative solutions tailored specifically for the Chinese healthcare landscape.

Their proactive approach to market presence is reflected in several strategic mergers and acquisitions aimed at enhancing their capabilities and expanding their reach in the infusion systems domain. This not only bolsters their position in the market but also ensures that healthcare providers have access to cutting-edge infusion technologies that can significantly improve patient outcomes.

### **Key Companies in the China Drug Infusion System Market Include**

- Zhejiang Shunfeng
- Becton Dickinson
- [Medtronic](https://www.medtronic.com/en-us/healthcare-professionals/products/wound-closure/sutures/absorbable-sutures.html#aq=%40pagetype%3D%22product-model%22&cq=%40products_type%3D%22Absorbable%20sutures%22%20OR%20%40ontology_isa%3D%22Absorbable%20sutures%22)
- Fresenius Kabi
- Mediware
- Terumo
- Smiths Medical
- Smith Nephew
- Johnson Johnson
- Shandong Zhushi Pharmaceutical
- Kangjie Medical
- Hunan Jisheng Medical
- B. Braun
- IV Solutions
- CME Medical

### **China Drug Infusion System Market Industry Developments**

Recent developments in the China Drug Infusion System Market reflect a dynamic landscape marked by increasing technological advancements and regulatory changes. Companies like Becton Dickinson, Medtronic, and Fresenius Kabi are ramping up their product offerings to meet the growing demand for innovative drug delivery systems driven by an expanding healthcare infrastructure. According to government sources, the Chinese government continues to enhance its healthcare policies, which is positively impacting the market growth.

In terms of mergers and acquisitions, there have been notable activities, such as Zhejiang Shunfeng's acquisition of Hunan Jisheng Medical in September 2023, further consolidating its market position. Additionally, B. Braun has expanded its operations in China by establishing new production facilities to increase local manufacturing capabilities, enhancing supply chain efficiency. The Chinese Drug Infusion System Market is projected to witness significant growth due to rising chronic disease prevalence and increasing healthcare expenditures, with companies like Johnson and Johnson and Terumo actively participating in this growth trajectory.

Over the past few years, investments in Research and Development have surged, indicating a robust focus on innovative solutions to improve patient outcomes.

### **China Drug Infusion System Market Segmentation Insights**

#### **Drug Infusion System Market Product Type Outlook**

- Elastomeric Infusion System
- Disposable Infusion System

#### **Drug Infusion System Market Application Outlook**

- Oncology/Chemotherapy

#### **Drug Infusion System Market Mode of Administration Outlook**

- Intravenous

#### **Drug Infusion System Market End User Outlook**

- Hospitals

## Market Drivers

### Integration of Smart Technologies

The integration of smart technologies into drug infusion systems is transforming the landscape of the market in China. Advanced features such as real-time monitoring, automated dosage adjustments, and connectivity with mobile applications are becoming increasingly prevalent. These innovations enhance the efficiency and accuracy of drug delivery, thereby improving patient outcomes. The market is projected to grow as healthcare facilities adopt these smart systems to streamline operations and reduce medication errors. It is estimated that the adoption of smart infusion systems could lead to a reduction in adverse drug events by up to 30%. This technological evolution is likely to drive the drug infusion-system market forward, as healthcare providers seek to leverage technology for better patient care.

### Government Initiatives and Funding

Government initiatives and funding play a crucial role in shaping the drug infusion-system market in China. The government has been actively promoting healthcare reforms aimed at improving access to advanced medical technologies. Increased funding for healthcare infrastructure and innovation is likely to enhance the availability of drug infusion systems across various healthcare settings. Additionally, public health campaigns aimed at raising awareness about the benefits of infusion therapy are expected to further stimulate market growth. With the government's commitment to enhancing healthcare delivery, the drug infusion-system market is poised for expansion, potentially reaching a valuation of $2 billion by 2027.

### Growing Focus on Personalized Medicine

The drug infusion-system market in China is witnessing a growing focus on personalized medicine, which tailors treatment to individual patient needs. This approach is becoming increasingly relevant as healthcare providers recognize the importance of customized therapies in improving patient outcomes. Infusion systems that can accommodate personalized drug regimens are in high demand, as they allow for precise dosing and monitoring. The trend towards personalized medicine is likely to drive innovation within the drug infusion-system market, as manufacturers develop systems that can adapt to varying patient requirements. This shift is expected to contribute to a market growth rate of approximately 9% over the next five years, reflecting the increasing emphasis on individualized treatment strategies.

### Increasing Prevalence of Chronic Diseases

The drug infusion-system market in China is significantly influenced by the rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders. According to recent statistics, chronic diseases account for approximately 80% of all healthcare expenditures in the country. This alarming trend necessitates effective management strategies, including the use of drug infusion systems for continuous medication delivery. As the population ages and lifestyle-related health issues become more common, the demand for reliable infusion systems is expected to escalate. The market is anticipated to grow at a CAGR of around 8% over the next few years, driven by the urgent need for effective treatment options for chronic conditions.

### Rising Demand for Home Healthcare Solutions

The drug infusion-system market in China is experiencing a notable surge in demand for home healthcare solutions. This trend is driven by an increasing aging population, which is projected to reach 400 million by 2040. As more patients prefer receiving treatment at home, the market for drug infusion systems is likely to expand significantly. Home healthcare not only reduces hospital visits but also enhances patient comfort and satisfaction. The convenience of administering medications at home is appealing to both patients and healthcare providers. Consequently, the drug infusion-system market is expected to witness a compound annual growth rate (CAGR) of approximately 10% over the next five years, reflecting the growing preference for home-based care solutions.

## Future Outlook

The [Drug Infusion System Market](https://www.marketresearchfuture.com/reports/drug-infusion-system-market-6207) in China is projected to grow at a 5.34% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare demands.

**New opportunities:**

- Development of smart infusion pumps with IoT connectivity
- Expansion of home healthcare infusion services
- Integration of AI for personalized medication delivery

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Product Type: Syringe infusion system (Largest) vs. Elastomeric infusion system (Fastest-Growing)

In the China drug infusion-system market, the distribution of market share among product types showcases the syringe infusion system as the largest segment, attributed to its widespread utilization in healthcare facilities. Following closely is the disposable infusion system, alongside the emerging elastomeric infusion system, which has gained traction due to its user-friendly features and efficiency in drug delivery. Other notable segments include peristaltic and multi-channel pumps, both contributing to a diverse market landscape.

The growth trends in this segment are driven by advancements in technology and an increase in chronic diseases requiring continuous drug administration. The rising preference for home care settings has also propelled demand for portable and user-centric infusion systems, with elastomeric infusion systems leading the charge as the fastest-growing category in the market, indicating a shift towards more flexible treatment options.

Syringe infusion system (Dominant) vs. Elastomeric infusion system (Emerging)

The syringe infusion system is a dominant player in the China drug infusion-system market, favored for its reliability and accuracy in medication delivery. This system is commonly used in hospitals and outpatient settings, offering a straightforward solution for healthcare providers. In contrast, the elastomeric infusion system is an emerging segment, characterized by its autonomy and ease of use. These systems, which utilize a balloon-like device to deliver medication, are increasingly recognized for their benefits in patient-controlled administration and convenience. The growth of the elastomeric infusion system is indicative of a shift towards more innovative, patient-friendly solutions that enhance treatment efficacy and compliance.

### By Application: Oncology/Chemotherapy (Largest) vs. Diabetes (Fastest-Growing)

In the China drug infusion-system market, the Oncology/Chemotherapy segment holds the largest market share, driven by the rising incidence of cancer cases and the increasing adoption of advanced treatment protocols. Following closely is the Diabetes segment, which is experiencing robust growth due to the alarming rise in diabetes prevalence and the demand for effective management solutions. This competitive landscape highlights the importance of innovation in drug delivery systems for chronic conditions.

Growth trends indicate that while Oncology/Chemotherapy remains dominant, the Diabetes sector is set to outpace traditional segments significantly. Factors such as increased healthcare expenditure, technological advancements in drug delivery, and expanding patient awareness contribute to the rapid growth of the diabetes infusion systems. Furthermore, emerging trends in personalized medicine and continuous monitoring are expected to propel the market forward, particularly for the Diabetes segment.

Oncology/Chemotherapy (Dominant) vs. Diabetes (Emerging)

The Oncology/Chemotherapy segment is characterized by a diverse range of infusion systems designed for administering chemotherapeutic agents. Its dominance stems from extensive research and development investments, driving innovation in drug delivery techniques that enhance efficacy and patient comfort. Conversely, the Diabetes segment is emerging rapidly, primarily due to the increasing prevalence of diabetes among the population. The infusion systems in this category are crucial for providing consistent insulin delivery to manage blood sugar levels effectively. The growing trend towards home care and the development of user-friendly, advanced delivery systems are key drivers that support the rising popularity of diabetes products, positioning them favorably for future growth.

### By Mode of administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing)

The China drug infusion-system market demonstrates a diverse distribution of market share among its mode of administration segments. Intravenous administration commands the largest share, as it is the most commonly used method for delivering medications directly into the bloodstream. Subcutaneous administration is witnessing notable growth, appealing to patient convenience and the rise in home care and self-administration practices. Arterial, epidural, and other methods contribute to the market but remain comparatively smaller in share.

Growth trends in the mode of administration segment are driven by factors such as an increased demand for active and chronic disease management, advancements in infusion technology, and an emphasis on non-invasive treatment methods. Intravenous delivery maintains its prominence due to its efficiency in drug administration. In contrast, the subcutaneous route is emerging rapidly, supported by innovations that enhance patient experience and facilitate outpatient care, making it a preferred option for many healthcare providers.

Intravenous (Dominant) vs. Subcutaneous (Emerging)

Intravenous administration is recognized as the dominant method in the China drug infusion-system market, primarily due to its wide acceptance in acute care settings and the efficiency it offers in drug delivery. This method allows for rapid onset of action, making it crucial for critically ill patients requiring immediate treatment. Conversely, the subcutaneous method is emerging as a viable alternative, particularly appealing for long-term treatments and patient self-management. Its growth is fueled by technological advancements that make devices easier to use and more comfortable for patients. Both methods highlight significant trends in patient-centered care, with intravenous methods standing out for acute interventions, while subcutaneous administration is gaining traction in managing chronic conditions outside of clinical settings.

### By End-user: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the China drug infusion-system market, hospitals hold the largest share, dominating the overall distribution of end-user segments. This is largely attributed to their extensive infrastructure and high volume of inpatient procedures requiring drug infusion systems. Ambulatory surgical centers, while smaller in market share, are rapidly gaining ground, driven by the increasing preference for outpatient services that promise lower costs and shorter recovery times. 

Growth trends indicate a robust expansion in both hospitals and ambulatory surgical centers. The shift towards minimally invasive surgeries and outpatient care is propelling the demand for advanced drug infusion systems. Hospitals are adapting to technological advancements, while ambulatory surgical centers benefit from the rising patient preference for convenience and efficiency in healthcare delivery, marking them as a significant player in the market's future.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals, as the dominant segment in the China drug infusion-system market, showcase a comprehensive integration of advanced medical technology that caters to diverse inpatient needs. They typically facilitate a wide range of drug infusion therapies, supported by specialized staff and vast resources. In contrast, ambulatory surgical centers are emerging as pivotal players, focusing on cost-effective and efficient treatment for outpatient procedures. These centers are characterized by their streamlined operations and patient-centric services, offering a more accessible alternative to traditional hospital settings. The growing trend among patients to seek quicker recovery options and reduced hospital stays is likely to bolster the market position of ambulatory surgical centers significantly in the coming years.

## Competitive Benchmarking

The drug infusion-system market in China is characterized by a dynamic competitive landscape, driven by technological advancements and increasing healthcare demands. Major players such as Baxter International (US), B. Braun Melsungen AG (DE), and Medtronic (US) are strategically positioned to leverage innovation and regional expansion. Baxter International (US) focuses on enhancing its product portfolio through continuous innovation, while B. Braun Melsungen AG (DE) emphasizes partnerships to strengthen its market presence. Medtronic (US) is actively pursuing digital transformation initiatives, which collectively shape a competitive environment that prioritizes advanced solutions and customer-centric approaches.Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a diverse range of products and services, catering to varying customer needs while fostering healthy competition among established and emerging companies.

In September  Baxter International (US) announced the launch of a new infusion pump designed to improve patient safety and streamline workflows in clinical settings. This strategic move underscores Baxter's commitment to innovation and positions the company to capture a larger market share by addressing critical healthcare challenges. The introduction of this advanced technology is likely to enhance Baxter's competitive edge in a rapidly evolving market.

In October  B. Braun Melsungen AG (DE) expanded its manufacturing capabilities in China by investing €50 million in a new facility. This investment not only signifies B. Braun's dedication to local production but also aims to meet the growing demand for infusion systems in the region. By localizing its operations, B. Braun is expected to improve supply chain efficiency and reduce lead times, thereby enhancing its competitive positioning.

In August  Medtronic (US) entered into a strategic partnership with a leading Chinese healthcare provider to integrate AI-driven analytics into its infusion systems. This collaboration is anticipated to enhance patient monitoring and optimize treatment protocols, reflecting Medtronic's focus on digital health solutions. The integration of AI technology is likely to set a new standard in the market, further differentiating Medtronic from its competitors.

As of November  current trends in the drug infusion-system market include a strong emphasis on digitalization, sustainability, and AI integration. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technology, and supply chain reliability. This transition may redefine market dynamics, compelling companies to invest in advanced solutions that enhance patient outcomes and operational efficiency.

## Recent News & Developments

Recent developments in the China Drug Infusion System Market reflect a dynamic landscape marked by increasing technological advancements and regulatory changes. Companies like Becton Dickinson, Medtronic, and Fresenius Kabi are ramping up their product offerings to meet the growing demand for innovative drug delivery systems driven by an expanding healthcare infrastructure. According to government sources, the Chinese government continues to enhance its healthcare policies, which is positively impacting the market growth.

In terms of mergers and acquisitions, there have been notable activities, such as Zhejiang Shunfeng's acquisition of Hunan Jisheng Medical in September 2023, further consolidating its market position. Additionally, B. Braun has expanded its operations in China by establishing new production facilities to increase local manufacturing capabilities, enhancing supply chain efficiency. The Chinese Drug Infusion System Market is projected to witness significant growth due to rising chronic disease prevalence and increasing healthcare expenditures, with companies like Johnson and Johnson and Terumo actively participating in this growth trajectory.

Over the past few years, investments in Research and Development have surged, indicating a robust focus on innovative solutions to improve patient outcomes.

## Report Scope

| MARKET SIZE 2024 | 740.25(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 779.78(USD Million) |
| MARKET SIZE 2035 | 1312.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.34% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Baxter International (US), B. Braun Melsungen AG (DE), Medtronic (US), Smiths Medical (US), Fresenius Kabi (DE), Terumo Corporation (JP), ICU Medical (US), Halyard Health (US), Zyno Medical (US) |
| Segments Covered | Product Type, Application, Mode of administration, End-user |
| Key Market Opportunities | Integration of smart technology in drug infusion systems enhances patient safety and operational efficiency. |
| Key Market Dynamics | Rising demand for advanced drug infusion systems driven by regulatory changes and technological innovations in healthcare. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What is the projected market valuation for the China drug infusion-system market in 2035?**
A: The projected market valuation for the China drug infusion-system market in 2035 is $1312.0 Million.

**Q: What was the overall market valuation in 2024?**
A: The overall market valuation in 2024 was $740.25 Million.

**Q: What is the expected CAGR for the China drug infusion-system market during the forecast period 2025 - 2035?**
A: The expected CAGR for the China drug infusion-system market during the forecast period 2025 - 2035 is 5.34%.

**Q: Which product type had the highest valuation in 2024?**
A: In 2024, the disposable infusion system had the highest valuation at $148.06 Million.

**Q: What is the projected valuation for the oncology/chemotherapy application by 2035?**
A: The projected valuation for the oncology/chemotherapy application by 2035 is $263.0 Million.

**Q: Which end-user segment is expected to dominate the market in 2035?**
A: The hospitals segment is expected to dominate the market in 2035 with a projected valuation of $683.4 Million.

**Q: What was the valuation of the insulin pump segment in 2024?**
A: The valuation of the insulin pump segment in 2024 was $37.01 Million.

**Q: Which key player is known for its leadership in the drug infusion-system market?**
A: Baxter International is recognized for its leadership in the drug infusion-system market.

**Q: What is the projected valuation for the multi-channel pump segment by 2035?**
A: The projected valuation for the multi-channel pump segment by 2035 is $130.0 Million.

**Q: How does the valuation of the subcutaneous mode of administration compare in 2024 and 2035?**
A: The valuation of the subcutaneous mode of administration is expected to increase from $148.05 Million in 2024 to $250.0 Million in 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-drug-infusion-system-market-56548*